Mesio-Temporal Lobe Epilepsy (MTLE)
Also called Focal, Drug-refractory or Drug-resistant epilepsy, Mesio-Temporal Lobe Epilepsy (MTLE) is an epileptic condition for which no effective or satisfactory treatment exists to date.
With over 10% of the total epileptic population affected, MTLE is a major challenge for patients as most pharmacological treatments have no effect on these seizures.
How about addressing the disease with a preclinical model that mimicks human MTLE?
clinically-relevant model of mtle
The MTLE mouse model is non-convulsive. Seizures are monitored within the brain and cannot be assessed without appropriate EEG methods.
Pr. Karen S. Wilcox, Chair of Pharmacology and Toxicology at University of Utah
We find in SynapCell a predictive rodent model of therapy-resistant MTLE that supplements our evaluation capabilities and addresses an important recommendation of the NINDS Working Group.
From HIT ID to LEAD Validation
Augmented by our EEG capabilities (Cue), you can use the MTLE model for several applications, including the screening of a small library of compounds, performing dose-response studies or assessing the disease-modifying potential of your compound on epileptogenesis (anti-epileptogenic effect). The model is also relevant to evaluate the potentiating or synergistic effects of an AED when combined to other drugs and identify the most effective drug associations.
Combine a MTLE study (focal epilepsy) with a GAERS study (generalized epilepsy) to derisk your compounds, identify seizure-aggravating effects and more importantly, align your preclinical strategy with your clinical roadmap to validate your AED.